Navigation Links
Study Confirms Passive Safety Devices Are Most Effective in Needlestick Injury Prevention

BETHLEHEM, Pa., Oct. 26 /PRNewswire/ -- A landmark study of 22 million safety devices used in 61 French hospitals over a two-year period has confirmed the theory that passive, fully automatic safety devices offer significantly better protection against accidental needlestick injuries (NSIs) than early generation active safety technologies such as semi-automatic (push-button) devices or those with manually sliding shields or hinged caps.



This study, described in the article "Needlestick Injury Rates According to Different Types of Safety-Engineered Devices: Results of a French Multicenter Study" in the April 2010 issue of Infection Control and Hospital Epidemiology, was the first head-to-head comparison of safety-engineered devices by safety technology type. It was conducted by GERES (Groupe d'Etude sur le Risque d'Exposition des Soignants), a well-established, government-funded research group.

The study concludes that passive safety engineered devices are more effective than active devices for NSI prevention.

Among its findings, the study documents the procedure specific needlestick injury rate by safety device technology. For intravascular catheters the NSI rate for passive or fully automatic devices studied was 1.31 per 100,000 devices used, compared with 2.54 per 100,000 devices used for semi-automatic (push-button) technology and 4.34 per 100,000 devices used for manually sliding shield technology. With semi-automatic and sliding shield devices, healthcare workers can choose whether or not to operate the safety features. Passive, fully automatic devices, on the other hand, "require no input from the user" and "eliminate the need for elaborate training." According to the study, fully automatic or passive safety devices are most effective for NSI prevention. The B. Braun Medical Inc. (B. Braun) Introcan Safety® IV Catheter was one of the devices used in this study and is a market share leader in fully automatic, passive safety technology IV catheters.

"Automatic safety features in catheters are critical to reducing accidental needlestick injuries," said Lynn Hadaway, M.Ed., RN, BC, CRNI, who has more than 35 years experience in infusion nursing and adult education. "The study clearly demonstrates why healthcare facilities need to carefully select devices on the basis of their passive safety features." Hadaway recently recorded her thoughts on the significance of this study and that video can be accessed here.

Janine Jagger, Director of the International Healthcare Workers Safety Center at the University of Virginia said the study "may never be replicated because of its sheer size – involving 22 million needle devices."

"The researchers have demonstrated that devices requiring the least manipulation to cover the needles have the lowest injury rates - passive devices being the lowest," she said. "This is the same phenomenon that was first demonstrated more than 20 years ago, but with comparisons at that time to conventional needles. The technological advances since then have been amazing. We should not forget that all of these safety designs are significantly safer than conventional needles."

"This study adds a critical new layer of evidence supporting the adoption and use of safety engineered devices to prevent healthcare worker injuries and exposure to blood borne pathogens like hepatitis C and HIV. It provides conclusive evidence of the increased protection fully automatic devices provide when compared with other early generation safety-engineered devices," said Tom Sutton, Vice President, Vascular Access and IV Systems for B. Braun Medical Inc. "The study shows a passive, fully automatic safety IV catheter is about two times better than an active, semi-automatic 'push-button' safety shield and three times better than a manually sliding shield technology in preventing NSIs."

With B. Braun's Introcan Safety® IV Catheter, for example, all the user has to do is use it, as the safety mechanism does not require any extra steps for activation. There is no risk of forgetting to make the needle safe. From insertion to advancing the catheter to needle removal, clinicians are protected because they are using a fully automatic passive safety device that cannot be bypassed.

Sutton added that the GERES study is likely to influence purchasing trends as healthcare professionals evaluate the most appropriate devices for their facilities.

If you would like more information or a copy of the study, please click here.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, email us at or visit B. Braun at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
5. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
6. INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine
7. Despite Potential Risk of Serious Birth Defects, New Study Finds Poor Adherence to Oral Contraception among Women on Category X Medications
8. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
9. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
10. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
11. IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):